Tina Pesaran

6.1k citations

43 papers · 1.9k indexed · 2 hit papers · h-index 16

Co-authors: Jill S. Dolinsky Heidi L. Rehm Steven M. Harrison Elizabeth Chao Holly LaDuca Leslie G. Biesecker Marina T. DiStefano Ahmad Abou Tayoun
Topics: Genomics and Rare Diseases (20 papers)BRCA gene mutations in cancer (18 papers)Cancer Genomics and Diagnostics (17 papers)
Cited by: Genetics Cancer Research Pathology and Forensic Medicine
Journals: New England Journal of Medicine Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United States Australia United Kingdom

In The Last Decade

Tina Pesaran

41 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion

2018 433 citations Tina Pesaran, Heidi L. Rehm et al. Human Mutation profile →
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

2017 393 citations Fergus J. Couch, Hermela Shimelis et al. profile →

Peers

Countries citing papers authored by Tina Pesaran

Since Specialization

Citations

This map shows the geographic impact of Tina Pesaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina Pesaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina Pesaran more than expected).

Fields of papers citing papers by Tina Pesaran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina Pesaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina Pesaran. The network helps show where Tina Pesaran may publish in the future.

Co-authorship network of co-authors of Tina Pesaran

This figure shows the co-authorship network connecting the top 25 collaborators of Tina Pesaran. A scholar is included among the top collaborators of Tina Pesaran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina Pesaran. Tina Pesaran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53 2025 ·Human Genetics and Genomics Advances ·Cristina Fortuño,Marcy E. Richardson,Tina Pesaran,Kelly McGoldrick,Paul A. James,Amanda B. Spurdle	0
2	Assigning credit where it is due: an information content score to capture the clinical value of multiplexed assays of variant effect 2024 ·BMC Bioinformatics ·John Michael O. Rañola,Carolyn Horton,Tina Pesaran,Shawn Fayer,Lea M. Starita,Brian H. Shirts	1
3	ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification 2023 ·The American Journal of Human Genetics ·Leslie G. Biesecker,Alicia B. Byrne,(unknown),Tina Pesaran,Alejandro A. Schäffer,Brian H. Shirts,(unknown),(unknown)	32
4	An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance 2022 ·npj Genomic Medicine ·Edwin S. Iversen,(unknown),Steven N. Hart,Kun Y. Lee,Chunling Hu,Eric C. Polley,Tina Pesaran,Amal Yussuf,Holly LaDuca,Elizabeth Chao,Rachid Karam,David E. Goldgar,Fergus J. Couch,Álvaro N.A. Monteiro	4
5	Classification of the canonical splice alteration MUTYH c.934-2A > G is likely benign based on RNA and clinical data 2021 ·Molecular Case Studies ·Felicia Hernandez,(unknown),Marcy E. Richardson,Holly LaDuca,(unknown),Tina Pesaran,Rachid Karam	1
6	Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance 2021 ·The American Journal of Human Genetics ·Marcy E. Richardson,Chunling Hu,Kun Y. Lee,Holly LaDuca,(unknown),(unknown),(unknown),(unknown),Álvaro N.A. Monteiro,Rohan Gnanaolivu,Steven N. Hart,Eric C. Polley,Elizabeth Chao,Tina Pesaran,Fergus J. Couch	29
7	Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN 2021 ·The American Journal of Human Genetics ·Shawn Fayer,Carolyn Horton,Jennifer N. Dines,Alan F. Rubin,Marcy E. Richardson,Kelly McGoldrick,Felicia Hernandez,Tina Pesaran,Rachid Karam,Brian H. Shirts,Douglas M. Fowler,Lea M. Starita	53
8	Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines 2020 ·Human Mutation ·Cristina Fortuño,Jessica L. Mester,Tina Pesaran,Jeffrey N. Weitzel,Jill S. Dolinsky,Amal Yussuf,Kelly McGoldrick,Judy E. Garber,Sharon A. Savage,Payal P. Khincha,D. Gareth Evans,Maria Isabel Achatz,Kim E. Nichols,Kara N. Maxwell,Joshua D. Schiffman,Renata Lazari Sandoval,Paul A. James,Amanda B. Spurdle	14
9	The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort 2020 ·JNCI Journal of the National Cancer Institute ·Chunling Hu,Eric C. Polley,Siddhartha Yadav,Jenna Lilyquist,Hermela Shimelis,Jie Na,Steven N. Hart,David E. Goldgar,Swati Shah,Tina Pesaran,Jill S. Dolinsky,Holly LaDuca,Fergus J. Couch	62
10	p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients 2019 ·Cancer Genetics ·Cristina Fortuño,Tina Pesaran,Jill S. Dolinsky,Amal Yussuf,Kelly McGoldrick,Pik Fang Kho,Paul A. James,Amanda B. Spurdle	11
11	REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification 2019 ·Scientific Reports ·Yuan Tian,Tina Pesaran,Adam Chamberlin,R. Bryn Fenwick,Shuwei Li,Chia‐Ling Gau,Elizabeth Chao,Hsiao‐Mei Lu,Mary Helen Black,Dajun Qian	58
12	Gene‐specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel 2018 ·Human Mutation ·Jessica L. Mester,Rajarshi Ghosh,Tina Pesaran,Robert Huether,Rachid Karam,Kathleen S. Hruska,Helio A. Costa,Katherine Lachlan,Joanne Ngeow,Jill S. Barnholtz‐Sloan,(unknown),Felicia Hernandez,Liying Zhang,Laura V. Milko,Sharon E. Plon,Madhuri Hegde,Charis Eng	89
13	Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants 2018 ·Human Mutation ·Cristina Fortuño,Paul A. James,Erin L. Young,Bing Feng,Magali Olivier,Tina Pesaran,Sean V. Tavtigian,Amanda B. Spurdle	27
14	A Bayesian framework for efficient and accurate variant prediction 2018 ·PLoS ONE ·Dajun Qian,Shuwei Li,Yuan Tian,(unknown),Brice A. J. Sarver,Tina Pesaran,Chia‐Ling Gau,Aaron Elliott,Hsiao‐Mei Lu,Mary Helen Black	10
15	DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes 2018 ·Genetics in Medicine ·Marcy E. Richardson,Hansook Kim Chong,Wenbo Mu,(unknown),Vickie Hsuan,(unknown),Stéphanie Lam,(unknown),Tina Pesaran,Adam Chamberlin,Minsun Park,Phillip Gray,Rachid Karam,Aaron Elliott	15
16	Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar 2017 ·Genetics in Medicine ·Steven M. Harrison,Jill S. Dolinsky,Amy E. Knight Johnson,Tina Pesaran,Danielle R. Azzariti,Sherri J. Bale,Elizabeth Chao,Soma Das,Lisa M. Vincent,Heidi L. Rehm	145
17	ClinGen and Genetic Testing. 2015 ·New England Journal of Medicine ·Rachid Karam,Tina Pesaran,Elizabeth Chao	1
18	Processed Pseudogene Confounding Deletion/Duplication Assays for SMAD4 2015 ·Journal of Molecular Diagnostics ·Alison Millson,Tracey Lewis,Tina Pesaran,David Salvador,(unknown),Chia‐Ling Gau,Geneviève Pont-Kingdon,Elaine Lyon,Pınar Bayrak‐Toydemir	14
19	Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients 2014 ·Genetics in Medicine ·Holly LaDuca,Aaron J. Stuenkel,Jill S. Dolinsky,Steven Keiles,(unknown),Tina Pesaran,Elaine Chen,Chia‐Ling Gau,Erika Palmaer,(unknown),Divya Shah,Virginia Speare,Stephanie Gandomi,Elizabeth Chao	237
20	The Diet1 Locus Confers Protection against Hypercholesterolemia through Enhanced Bile Acid Metabolism 2002 ·Journal of Biological Chemistry ·Jack Phan,Tina Pesaran,Richard C. Davis,Karen Reue	23

About Tina Pesaran

Tina Pesaran is a scholar working on Genetics, Cancer Research and Pathology and Forensic Medicine, having authored 43 papers that have together received 1.9k indexed citations. Recurring topics across this work include Genomics and Rare Diseases (20 papers), BRCA gene mutations in cancer (18 papers) and Cancer Genomics and Diagnostics (17 papers). The work is most often cited by research in Genetics (1.2k citations), Cancer Research (567 citations) and Pathology and Forensic Medicine (379 citations). Tina Pesaran has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Jill S. Dolinsky, Heidi L. Rehm, Steven M. Harrison, Elizabeth Chao, Holly LaDuca, Leslie G. Biesecker, Marina T. DiStefano, Ahmad Abou Tayoun, Andrea M. Oza and Chunling Hu. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact